Zivo Bioscience Inc's Corporate Customers have recorded an advance in their cost of revenue by 8.45 % in the 3 quarter 2025 year on year, sequentially costs of revenue grew by 6.37 %. During the corresponding time, Zivo Bioscience Inc recorded a revenue increase by 108.33 % year on year, sequentially revenue grew by 22.89 %. While revenue at the Zivo Bioscience Inc 's corporate clients recorded rose by 3.2 % year on year, sequentially revenue grew by 4.5 %.
Zivo Bioscience Inc's Customers have recorded an advance in their cost of revenue by 8.45 % in the 3 quarter 2025 year on year, sequentially costs of revenue grew by 6.37 %, for the same period Zivo Bioscience Inc recorded revenue increase by 108.33 % year on year, sequentially revenue grew by 22.89 %.
Zivo Bioscience Inc's Comment on Sales, Marketing and Customers
ZIVO has partnered with Grupo Alimenta, a Peruvian agricultural conglomerate, to develop commercial-scale algae production at Alimenta Algae SAC in Peru, targeting an annual output of approximately 100,000 kilograms by 2027. ZIVO's subsidiary, ZIVOLife, LLC, will purchase the entire production under a contract manufacturing agreement. In June 2023, ZIVOLife commenced commercial shipments of dried green algae powder for human consumption, marketed under the brand Zivolife™ by ZWorldwide, Inc., a Miami-based marketing and distribution company. The primary market focus is the North American green powder food sector, with ZWorldwide selling directly to consumers through an online platform. The offtake agreement with ZWorldwide includes purchasing all ZIVOLife production through 2024 and a minimum of 24,000 kilograms per year for five years thereafter. Additionally, ZIVO may explore therapeutic applications, including treatments for avian influenza and bovine mastitis, subject to securing further funding.
ZIVO Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech RandD company, recently reported highly favorable results from a 42-day study targeting coccidiosis in broiler chickens. This study, conducted with a major global animal health company, mirrors real-world poultry production environments, indicating promising commercial potential for ZIVO s coccidiosis treatment. This is a significant breakthrough considering the high impact of coccidiosis on the poultry industry, which can lead to substantial economic losses. The Study Findings: A Closer Look The 42-day study is a testament to ZIVO’s innovative approach to animal health. Coccidiosis is a pervasive and costly disease in the poultry industry. E...
Zivo Bioscience Inc’s Comment on Sales, Marketing and Customers
ZIVO has partnered with Grupo Alimenta, a Peruvian agricultural conglomerate, to develop commercial-scale algae production at Alimenta Algae SAC in Peru, targeting an annual output of approximately 100,000 kilograms by 2027. ZIVO's subsidiary, ZIVOLife, LLC, will purchase the entire production under a contract manufacturing agreement. In June 2023, ZIVOLife commenced commercial shipments of dried green algae powder for human consumption, marketed under the brand Zivolife™ by ZWorldwide, Inc., a Miami-based marketing and distribution company. The primary market focus is the North American green powder food sector, with ZWorldwide selling directly to consumers through an online platform. The offtake agreement with ZWorldwide includes purchasing all ZIVOLife production through 2024 and a minimum of 24,000 kilograms per year for five years thereafter. Additionally, ZIVO may explore therapeutic applications, including treatments for avian influenza and bovine mastitis, subject to securing further funding.
Sources:
Zivo Bioscience Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Zivo Bioscience Inc’s corporate clients.
For your research, we’ve provided 9 tables on Zivo Bioscience Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
100 %
0.46 % 